Stocktoria
Eton Pharmaceuticals, Inc. ETON
Eton Pharmaceuticals, Inc. (ETON) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $80.0M at a -5.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.3 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.24 |
| Retained earnings / assets | -1.221 |
| EBIT / assets | -0.009 |
| Equity / liabilities | 0.397 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ETON | Eton Pharmaceuticals, Inc. | 5/9 | -2.05 | — | +104.9% |
| ARCT | Arcturus Therapeutics Holdings Inc. | 1/9 | 0.81 | — | -46.1% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
| NRIX | Nurix Therapeutics, Inc. | 3/9 | 1.2 | — | +54% |
| SPRY | ARS Pharmaceuticals, Inc. | 3/9 | -1.13 | — | -5.5% |
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
| BCYC | BICYCLE THERAPEUTICS PLC | 1/9 | 5.27 | — | +105.8% |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
FAQ
Is ETON financially healthy?
Eton Pharmaceuticals, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ETON pay a dividend?
No, Eton Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is ETON?
In FY2025, Eton Pharmaceuticals, Inc. had a net margin of -5.8% and a return on equity of -17.6%.
What is the analyst price target for ETON?
The average Wall-Street price target for Eton Pharmaceuticals, Inc. is $45.67, about 9.8% above the recent price, from 3 analysts (consensus: strong buy).
Is ETON a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Eton Pharmaceuticals, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.